NeurogesX, which is developing pain management therapies based on known chemical entities, priced its 4 million shares at $11, 21% below the midpoint of the anticipated $13-$15 range, on Tuesday evening. Morgan Stanley was the lead manager on the deal. The stock is expected to begin trading on Wednesday on the NASDAQ under the ticker "NGSX."
